Paroxysmal atrial fibrillation
Methodology & AI Transparency ⓘ
Paroxysmal atrial fibrillation Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Paroxysmal atrial fibrillation—coded clinically as I48.0 across Heart & Vascular guidelines—combines cardiopulmonary biomarker stratification [Paroxysmal atrial fibrillation I48.0] with structured follow-up of Apolipoprotein B (ApoB) [Paroxysmal atrial fibrillation I48.0] (< 70 mg/dL (I48.0)).
- 2 Real-world patient consensus: Diagnostic registry I48.0: Paroxysmal atrial fibrillation is managed within Heart & Vascular.
- 3 Typical cash cost range: Clinicians assessing Paroxysmal atrial fibrillation focus on coronary microvascular remodeling [Paroxysmal atrial fibrillation I48.0] and targeted history.
- 4 Top reported side effects / signs: Longitudinal Paroxysmal atrial fibrillation monitoring tracks High-Sensitivity Troponin I [Paroxysmal atrial fibrillation I48.0] toward < 14 ng/L (I48.0).
Ask our AI Specialists anything about Paroxysmal atrial fibrillation
What Is Paroxysmal atrial fibrillation?
Paroxysmal atrial fibrillation—coded clinically as I48.0 across Heart & Vascular guidelines—combines cardiopulmonary biomarker stratification [Paroxysmal atrial fibrillation I48.0] with structured follow-up of Apolipoprotein B (ApoB) [Paroxysmal atrial fibrillation I48.0] (< 70 mg/dL (I48.0)).
Pathophysiology, Underlying Causes & Clinical Presentation
In Paroxysmal atrial fibrillation (I48.0), physiological disruption stems from coronary microvascular remodeling [Paroxysmal atrial fibrillation I48.0], informing Heart & Cardiovascular Disease protocols that track Apolipoprotein B (ApoB) [Paroxysmal atrial fibrillation I48.0] (< 70 mg/dL (I48.0)).
Common Symptoms & Clinical Signs
- • Presentation of Paroxysmal atrial fibrillation (I48.0): exertional chest pressure in Paroxysmal atrial fibrillation (I48.0: or retrosternal tightness)
- • Secondary Paroxysmal atrial fibrillation clinical sign: shortness of breath in Paroxysmal atrial fibrillation (I48.0: when climbing stairs)
- • Symptom flares in Paroxysmal atrial fibrillation correlating with High-Sensitivity Troponin I [Paroxysmal atrial fibrillation I48.0] deviation outside < 14 ng/L (I48.0)
- • Functional heart & vascular impact requiring cardiopulmonary biomarker stratification [Paroxysmal atrial fibrillation I48.0] evaluation (I48.0)
Paroxysmal atrial fibrillation Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I48.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Heart & Cardiovascular Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: High-Sensitivity Troponin I [Paroxysmal atrial fibrillation I48.0] | < 14 ng/L (I48.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Apolipoprotein B (ApoB) [Paroxysmal atrial fibrillation I48.0] | < 70 mg/dL (I48.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Left Ventricular Ejection in Paroxysmal atrial fibrillation (I48.0: Fraction (LVEF)) | 55% – 70% (I48.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Paroxysmal atrial fibrillation
Treatment selection for Paroxysmal atrial fibrillation depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Paroxysmal atrial fibrillation)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Liraglutide on heart and blood vessel Outcomes in Patients With Diabetes With or: What a 835-Participant Study Found Based on these findings, liraglutide should be considered suitable for patients with T2D with or without a history of NYHA functional class I to III HF. Journal of the American College of Cardiology • 2020-03-17 • Randomized Controlled Trial | N = 835 | 93/100 | PMID 32164886 ↗ |
| Can This Approach Help? Inside the Latest Research on [The real-world benefits and safety of eculizumab biosimilar in patients with The study established the equivalent efficacy of biosimilar product Acveris and referent eculizumab product with the evidence of effective suppression of intravascular hemolysis in PNH patients along with a comparable... Terapevticheskii arkhiv • 2021-11-15 • Phase III Randomized Trial | N = 14 | 82/100 | PMID 36286657 ↗ |
| Can This Approach Help? Inside the Latest Research on Changes in hemoglobin and clinical outcomes drive improvements in fatigue, Fatigue and other self-reported outcomes were correlated with clinically meaningful improvements in clinical and hematological parameters. Annals of hematology • 2022-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 35869984 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of crovalimab versus eculizumab in complement inhibitor-naïve Over 24 weeks, 91% of patients achieved complete terminal complement inhibition with crovalimab. Annals of hematology • 2026-06-13 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42287326 ↗ |
| Can This Approach Help? Inside the Latest Research on Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Crovalimab's safety profile was consistent with eculizumab's and was generally comparable between C5i-naive and C5i-switched patients. European journal of haematology • 2025-02-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39535306 ↗ |
Paroxysmal atrial fibrillation Patient Community & “People Like Me” Threads
Filter Paroxysmal atrial fibrillation community threads and patient logs by age, biological sex, dosage, and treatment duration.